Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 6/20 | 0.62 |
| ▸ | SRD5A1 | P18405 | 5/20 | 0.62 |
| ▸ | AR | P10275 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9022278 | 1.00 | SRD5A2 (0.62) | SRD5A2SRD5A1AR | |
| SCHEMBL9022655 | 0.92 | SRD5A2 (0.58) | SRD5A2SRD5A1AR | |
| SCHEMBL9022658 | 0.92 | SRD5A2 (0.58) | SRD5A2SRD5A1AR | |
| SCHEMBL9022620 | 0.89 | SRD5A2 (0.68) | SRD5A2SRD5A1AR | |
| SCHEMBL9022031 | 0.89 | SRD5A2 (0.68) | SRD5A2SRD5A1AR | |
| SCHEMBL9022701 | 0.89 | SRD5A2 (0.68) | SRD5A2SRD5A1AR | |
| SCHEMBL9022700 | 0.89 | SRD5A2 (0.68) | SRD5A2SRD5A1AR | |
| SCHEMBL9022626 | 0.89 | SRD5A2 (0.68) | SRD5A2SRD5A1AR | |
| SCHEMBL9022021 | 0.89 | SRD5A2 (0.68) | SRD5A2SRD5A1AR | |
| SCHEMBL9022044 | 0.86 | SRD5A1 (0.64) | SRD5A2SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0484094-B1 | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | SANKYO CO (JP) | 1996-06-26 | — | — | EP | disclosed |
| US-5302621-A | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1994-04-12 | — | — | US | disclosed |
| EP-0484094-A2 | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | Sankyo Company Limited (JP) | 1992-05-06 | — | — | EP | disclosed |